Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

KRAS inhibitors prime cancer cells for macrophage-mediated destruction

Award Number: R01CA279259
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2023
PERIOD OF PERFORMANCE END DATE: 05/31/2028

Group Awards By:

View Award Description

KRAS inhibitors prime cancer cells for macrophage-mediated destruction - Project Summary Approximately 20% of all human cancers contain a mutation in the KRAS oncogene that drives their growth and metastasis. Novel KRAS inhibitors have recently been developed that disable these growth signals. Although they help patients live longer, KRAS inhibitors are unlikely to cure patients. For this reason, there is a need to identify more effective ways to treat KRAS mutant cancers. Based on the success of cancer immunotherapy, an appealing strategy has been to combine targeted therapies with agents that activate the immune system to attack. Macrophages are cells of the innate immune system and are often the most common infiltrating immune cell in solid tumors. The CD47/SIRPa axis is a key regulator of macrophage activation in the tumor microenvironment and acts as a “don’t eat me” signal. Anti-CD47 antibodies that block this macrophage immune checkpoint can stimulate macrophage activation against cancer. In this proposal, we hypothesize that KRAS inhibitors make cancer cells more vulnerable to macrophage-mediated destruction, and consequently, that KRAS inhibitors will synergize with anti-CD47 antibodies to eliminate KRAS mutant cancers. Our overall goal is to convert KRAS-targeted therapies into curative therapies by engaging macrophages as effectors. To investigate potential synergy between KRAS inhibitors and anti-CD47 antibodies, we have developed a novel in vitro co-culture assay to evaluate macrophage-mediated destruction of cancer. We will use this assay to measure synergy between KRAS inhibitors and anti-CD47 antibodies (Aim 1). We will investigate the mechanism of synergy by assessing how KRAS inhibitors change the expression and function of other immunoregulatory molecules on the surface of KRAS mutant cancer cells. Next, we will test the combination therapy in xenograft mouse models of KRAS mutant cancer to evaluate for enhanced anti-tumor immunity in vivo (Aim 2). Finally, we will investigate the effects of the combination therapy in immunocompetent, syngeneic tumor models to understand how the combination therapy alters interactions between the innate and adaptive immune systems. Overall, we propose a novel mechanism to enhance the efficacy of KRAS inhibitors by merging the fields of immuno-oncology and precision medicine. We expect our findings to provide the rationale for rapidly translating this combination strategy to the clinic to benefit patients with KRAS mutant cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Treatment Research	001	4	3/31/2026	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$155,610
2026	2025	WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH	455 MAIN ST	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Cancer Treatment Research	000	3	3/27/2026	NON-COMPETING CONTINUATION	-$155,610
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $446,063 )
2025	2025	WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH	455 MAIN ST	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Cancer Treatment Research	000	3	6/9/2025	NON-COMPETING CONTINUATION	$446,063
														Subtotal = $446,063

Issue Date FY: 2024 ( Subtotal = $423,760 )
2024	2024	WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH	455 MAIN ST	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Cancer Treatment Research	000	2	5/14/2024	NON-COMPETING CONTINUATION	$423,760
														Subtotal = $423,760

Issue Date FY: 2023 ( Subtotal = $446,063 )
2023	2023	WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH	455 MAIN ST	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Cancer Treatment Research	000	1	5/19/2023	NEW	$446,063
														Subtotal = $446,063

Grand Total All Awards = $1,315,886

Top

All Categories

About

Search

Reports

Data Submission

Award Information

KRAS inhibitors prime cancer cells for macrophage-mediated destruction

Award Number: R01CA279259

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2023

PERIOD OF PERFORMANCE END DATE: 05/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer